Speaker Spotlight: The Intersection of Hepatic Transporters and Drug-Induced Liver Injury: Preclinical Tools to Advance Mechanistic Understanding and Precision Medicine

Monday, October 17, 2022

9:30 AM – 10:30 AM ET

Location:Spotlight Stage 1, Exhibit Hall A&B

Spotlight Speaker(s)

Kim Brouwer, PharmD, PhD

Associate Dean for Research and Graduate Education William R. Kenan, Jr., Distinguished Professor
UNC Eshelman School of Pharmacy The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Moderator(s)

Mattie Hartauer

Graduate Student
University of North Carolina - Chapel Hill

Hepatic transport proteins play a key role in the disposition of many drugs and bile acids. Altered function of these transporters by drugs or disease may predispose patients to drug-induced liver injury (DILI). Important considerations in assessing drug interactions with hepatic transporters and bile acid-mediated DILI liability will be discussed. Preclinical tools used in drug discovery and development to identify mechanisms of interactions and prospectively predict hepatotoxic potential of new drug candidates will be highlighted.

Learning Objectives:

1. Understand the role of hepatic transport proteins as key determinants of drug disposition and hepatotoxicity
2. Identify key considerations in assessing drug interactions with bile acid transporters and liability for bile acid-mediated drug-induced liver injury
3. Describe examples of disease-mediated alterations in hepatic transporters that may impact hepatobiliary drug disposition and drug-induced liver injury
4. Discuss preclinical tools to identify mechanisms of bile acid-mediated drug-induced liver injury
5. Explain how modeling and simulation can be used to prospectively predict the hepatotoxic potential of new drug candidates and advance precision dosing in patients with altered function of hepatic transport proteins